Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexelizumab in CABG (PRIMO-CABG II)
NCT00088179Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2004
- Primary completion
- Oct 2005
- Modality
- Antibody Fragments, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing Pexelizumab with Placebo (2 arms). Primary endpoint: Composite of Mortality and Myocardial Infarction at 30 days. Started Jul 2004; status: completed.
02
Drugs
pexelizumab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT00088179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088179.